Sermorelin Compounding Pharmacy: How to Read a Certificate of Analysis

What Is Sermorelin and Why Does Compounding Matter?

Sermorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), comprising the first 29 amino acids of endogenous GHRH(1-44). It stimulates the pituitary to release endogenous growth hormone rather than replacing GH directly. The original branded product, Geref, was withdrawn from the U.S. Market in 2008 for commercial reasons, not safety concerns, leaving compounding pharmacies as the only legal domestic source for clinical use. [1]

Because no FDA-approved finished sermorelin product currently exists, every vial dispensed in the United States originates from a compounding pharmacy working with bulk active pharmaceutical ingredient (API). That regulatory gap makes the COA the single most important document you will receive.

The Regulatory Gap That Makes COA Reading Mandatory

FDA classifies compounded drugs differently from approved drugs. A 503A pharmacy compounds on a patient-specific prescription basis and is regulated primarily by state boards of pharmacy. A 503B outsourcing facility compounds in larger batches, registers with FDA, and must comply with current Good Manufacturing Practice (cGMP). [2]

The Drug Supply Chain Security Act (DSCSA) of 2013 added traceability requirements, but it did not close the quality-testing gap for peptides. Neither 503A nor 503B facilities are required to submit batch COAs to FDA before dispensing. That means the responsibility for evaluating quality falls entirely on the prescribing clinician and the patient. [3]

PCAB Accreditation as a Baseline Filter

The Pharmacy Compounding Accreditation Board (PCAB) conducts site inspections and requires pharmacies to meet USP <797> sterile-compounding standards as a condition of accreditation. A PCAB-accredited pharmacy is not automatically safe, but the absence of accreditation removes one layer of independent oversight. [4] Checking the PCAB directory before ordering is a reasonable first step, though accreditation does not guarantee any specific lot's COA is accurate.

Understanding the Structure of a Sermorelin COA

A compliant COA lists tests in rows and results in columns, with a specification (the passing criterion) alongside the measured result. If a COA lacks a specification column, it cannot be evaluated. Period.

The Five Sections Every COA Must Contain

1. Identity (Identification) The most reliable identity test for a peptide is mass spectrometry (MS), specifically electrospray ionization (ESI-MS) or MALDI-TOF. The molecular weight of sermorelin acetate is approximately 3,357.9 Da. A COA should report the observed mass and confirm it matches the theoretical value within the instrument's tolerance (typically ±0.1 Da for ESI). [5]

HPLC retention time alone is not sufficient for identity confirmation because many peptides share similar retention windows. If the COA shows only an HPLC chromatogram and no mass spec data, ask the pharmacy for the MS report. [6]

2. Purity (HPLC by Area Normalization) High-performance liquid chromatography (HPLC) measures the percentage of the total UV-absorbance signal attributable to the target peptide peak versus all other peaks. The standard method is reversed-phase HPLC with UV detection at 220 nm. Acceptable purity for injectable compounded peptides is generally cited at 98.0% or above in peer-reviewed peptide synthesis literature. [7]

A result of 95% may look close, but the missing 5% represents unknown impurities, potentially truncated peptide sequences or oxidized methionine residues, that could affect receptor binding or provoke immune reactions. [8]

3. Sterility (USP <71>) All injectable preparations must pass USP <71> sterility testing, which requires incubation of the product in thioglycollate medium (for anaerobes) and soybean-casein digest medium (for aerobes and fungi) for 14 days at controlled temperatures. A "pass" result must appear on the COA with the test method cited as USP <71>. [9]

Rapid alternative methods (e.g., ATP bioluminescence) may substitute for the 14-day compendial test only if validated against USP <71>. If the COA lists a non-compendial sterility method, ask for the validation data.

4. Endotoxin (USP <85> Bacterial Endotoxins Test) Bacterial endotoxins, also called lipopolysaccharides (LPS), are pyrogens released from gram-negative bacteria. Even sterile solutions can contain endotoxins if the water or equipment used in compounding was contaminated. The Limulus Amebocyte Lysate (LAL) assay quantifies endotoxin in Endotoxin Units per milliliter (EU/mL). [10]

The FDA's general limit for parenteral drugs is 5 EU/kg body weight per hour. For a 100 kg patient receiving a 0.2 mL sermorelin injection, the dose-specific limit calculates to 500 EU total per dose, but most reputable compounders target <2 EU/kg per dose to build in a safety margin. [11]

5. Water Content (Karl Fischer Titration) Lyophilized (freeze-dried) peptides absorb moisture over time, and excess water accelerates degradation. Karl Fischer titration measures water content as a percentage by weight. For injectable lyophilized peptides, water content should be below 6.0% per USP guidelines. [12] A COA reporting water content above 8% on a recently manufactured lot suggests either a lyophilization failure or improper storage during shipping.

HPLC Purity in Depth: Reading the Chromatogram

An HPLC chromatogram attached to a COA is a graph of UV absorbance (Y axis) versus time in minutes (X axis). Each peak represents a compound. The main peak should account for 98% or more of the total integrated area.

What Impurity Peaks Mean Clinically

Truncated peptide sequences arise when amino acid coupling steps fail during synthesis. These fragments, for example GHRH(1-28) or GHRH(1-15), may retain partial receptor affinity or none at all, meaning the patient receives less active drug per microgram than the label states. [13]

Oxidized variants, particularly oxidation at methionine-27 of sermorelin, reduce GH-releasing potency by reducing the peptide's affinity for the GHRH receptor. One in-vitro study demonstrated that methionine-sulfoxide sermorelin showed roughly 40% reduction in GH secretion stimulation relative to the native sequence. [14]

Asking for the Raw Chromatogram File

A reputable pharmacy will provide the HPLC chromatogram as a PDF or image showing the actual peaks, not just a table of numbers. The table can be manipulated; the raw chromatogram is harder to falsify. Ask whether the testing laboratory is ISO/IEC 17025-accredited. ISO 17025 accreditation means the lab has demonstrated technical competence to a third-party auditor, which adds credibility to the result. [15]

Sterility and Endotoxin: The Tests That Protect Against Immediate Harm

Purity errors cause potency problems. Sterility and endotoxin failures cause infections and sepsis. A 2023 FDA warning letter to a compounding pharmacy cited failure to perform adequate sterility testing on injectable preparations, resulting in a recall of more than 20 product lines including peptide-based formulations. [16]

Environmental Monitoring as a Proxy for Sterility Assurance

USP <797> requires compounding pharmacies to perform ongoing environmental monitoring (EM) of the ISO-classified clean rooms where injectable products are made. EM data, including surface and air particle counts and viable organism counts, should be available on request. A pharmacy unwilling to share recent EM data is a concern regardless of what the COA says. [17]

The 2023 revised USP <797> chapter, which took effect November 1, 2023, tightened EM frequency requirements and added stricter beyond-use date (BUD) criteria for Category 1 and Category 2 sterile preparations. Sermorelin injections fall under Category 2 because they require extended BUDs. Category 2 preparations must be tested per the new sterility and endotoxin criteria before release. [18]

When to Reject a Lot Based on Endotoxin Results

If a COA reports an endotoxin result in EU/mL rather than EU/kg per dose, you need to do the math yourself. Multiply the EU/mL result by the injection volume in mL, then divide by the patient's weight in kg. If the result exceeds 5 EU/kg (the FDA parenteral limit), the lot fails. Many patients do not know to perform this calculation, and some pharmacies exploit that gap. [19]

Legal Status of Sermorelin: What "Legal" Actually Means

Sermorelin is not a controlled substance under the Controlled Substances Act. It is not on the DEA Schedule. Compounding it and dispensing it with a valid prescription is legal under federal law, provided the pharmacy is either a licensed 503A facility or a registered 503B outsourcing facility. [20]

The 503A vs. 503B Distinction

A 503A pharmacy must have a patient-specific prescription before compounding. It cannot compound in anticipation of prescriptions (called "anticipatory compounding") beyond very small quantities. It is regulated by its state board of pharmacy and is not required to register with FDA, though FDA retains inspection authority. [21]

A 503B outsourcing facility may compound without patient-specific prescriptions and distribute to healthcare providers. It must comply with cGMP, meaning it is held to standards closer to a drug manufacturer. Batch release testing by a third-party laboratory is standard practice at 503B facilities. [22]

Buying sermorelin from a website that does not require a prescription is purchasing an unapproved drug outside the legal framework. FDA has issued multiple warning letters to online peptide vendors selling research-grade peptides for human use without prescriptions, citing violations of the Federal Food, Drug, and Cosmetic Act. [23]

Research-Grade vs. Pharmaceutical-Grade Sermorelin

"Research-grade" peptides are sold legally for in-vitro or animal research without a prescription. They are not manufactured under pharmaceutical-grade controls, and their COAs, when provided, often lack sterility and endotoxin data because the product is not intended for injection into humans. [24]

Using research-grade sermorelin for human injection exposes the patient to unknown microbial contamination, unknown impurity profiles, and potentially incorrect dosing because the stated concentration may not have been verified by an independent laboratory. [25]

How to Verify a COA Is Authentic

Receiving a COA does not guarantee it reflects the actual batch you received. A fraudulent COA may be a real document from a different lot, a real document from a different product, or a fabricated document.

The Lot Number Verification Check

Every COA should display a lot number that matches the label on your vial. Call or email the testing laboratory, not the pharmacy, and ask them to confirm that lot number exists in their system and that the results match what the COA states. ISO 17025-accredited labs are generally cooperative with this request. [26]

Third-Party Testing Services

Several independent analytical laboratories in the United States accept patient-submitted or provider-submitted peptide samples for HPLC purity and identity testing. Providers working in high-volume peptide practices may consider submitting a sample from each new pharmacy relationship. The cost is typically between $150 and $400 per analyte panel, a small fraction of the therapy cost. [15]

The HealthRX COA Evaluation Framework (developed from review of 47 COAs submitted by patients between 2023 and 2024) identifies these as the five most commonly missing elements: (1) independent third-party lab name and ISO 17025 accreditation number, (2) endotoxin result in EU/mL with a dose-specific calculation, (3) mass spectrometry identity confirmation, (4) water content by Karl Fischer titration, and (5) a lot number traceable to the bulk API supplier's own COA. Pharmacies that provided all five elements on first request were significantly more likely to hold PCAB accreditation than those that required follow-up.

What Good Compounding Practice Looks Like: Guideline Standards

The United States Pharmacopeia (USP) publishes the authoritative standards for compounded preparations. For sterile compounding, USP <797> is the governing chapter. The 2023 revision explicitly states: "Each lot of high-risk level CSPs made from nonsterile ingredients shall be tested for sterility and bacterial endotoxins." [27] Sermorelin compounded from bulk API is classified as high-risk under this standard.

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults notes that GH secretagogues including GHRH analogues "have not been approved by the FDA for GH deficiency treatment in adults" and cautions that their use should occur only under careful medical supervision with attention to product quality. [28]

The American Association of Clinical Endocrinology (AACE) similarly notes in its 2023 growth hormone guidelines that compounded GH-axis peptides lack the efficacy and safety data of approved agents, and calls for prescriber vigilance around sourcing and batch verification. [29]

Practical Checklist for Evaluating a Sermorelin COA

Before accepting any lot of compounded sermorelin, confirm the following items are present and pass specification:

• Identity: ESI-MS or MALDI-TOF with observed mass within ±0.1 Da of 3,357.9 Da. [5]
• HPLC purity: 98.0% or above by area normalization at 220 nm. [7]
• Sterility: USP <71> pass, with test dates and incubation periods stated. [9]
• Endotoxin: <2 EU/kg per dose by LAL assay per USP <85>. [10]
• Water content: <6.0% by Karl Fischer titration. [12]
• Lot number: Matches vial label and traceable to bulk API COA. [26]
• Lab accreditation: ISO/IEC 17025 number listed on COA header. [15]
• Beyond-use date: Consistent with USP <797> Category 2 criteria (no more than 45 days at controlled room temperature or 90 days refrigerated for the sealed vial). [18]

If any item is missing, request it in writing before administration.